Good MRI images: to Gad or not to Gad?
Gadolinium-based magnetic resonance imaging (MRI) contrast agents (Gad-CA) were formerly considered as alternatives to X-ray-employed iodinated media. Although originally thought to be nonnephrotoxic and proven to be nonhazardous in a healthy population, the Gad-CA safety issue is progressively more controversial in the high-risk group of end-stage renal disease (ESRD) patients. Recently, Gad-CAs have not only been blamed for harmless side effects such as dizziness or nausea but also for much more severe complications such as acute renal failure, pancreatitis, or even the development of so-called "nephrogenic systemic fibrosis" in patients with renal failure, culminating in the prohibition of gadodiamide (Omniscan) administration in ESRD patients and, due to renal-organ immaturity, in newborns and infants up to 1 year old. This editorial is written to give insights into the molecular structure of Gad-CAs as well as into the potential biochemical pathomechanisms underlying the aforementioned severe clinical manifestations. Furthermore, a review about the latest literature on Gad-CA nephrotoxicity is provided. Potential risk factors are mentioned and strategies to avoid deterioration of renal function are presented. Cases with Gad-CA-associated adverse events should be adequately documented and reported appropriately. MRI professionals should collaborate closely with their colleagues from other medical specialties to identify patients with adverse events.
Steen
Henning
H
Department of Cardiology, University Hospital Heidelberg, Heidelberg, Germany.
Schwenger
Vedat
V
D002648:Child; D003287:Contrast Media / Q000009:adverse effects; D005682:Gadolinium / Q000009:adverse effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000503:physiopathology; D008279:Magnetic Resonance Imaging / Q000379:methods* / Q000592:standards
D003287:Contrast Media; D005682:Gadolinium